Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Seroconversion to Islet Autoantibodies After Enterovirus Infection in Early Pregnancy.

Author:
  • Sabina Rešić Lindehammer
  • Hanna Honkanen
  • William Allan Nix
  • Maarit Oikarinen
  • Kristian Lynch
  • Ida Jönsson
  • Karel Marsal
  • Steven Oberste
  • Heikki Hyöty
  • Åke Lernmark
Publishing year: 2012
Language: English
Pages: 254-261
Publication/Series: Viral Immunology
Volume: 25
Issue: 4
Document type: Journal article
Publisher: Mary Ann Liebert, Inc.

Abstract english

Gestational enterovirus (EV) infections have been associated with an increased risk for type 1 diabetes in the offspring. We therefore analyzed non-diabetic mothers for EV exposure in early pregnancy in relation to type 1 diabetes HLA-DQ risk genotypes and seroconversion to islet autoantibodies during pregnancy. Non-diabetic mothers who had islet autoantibodies (n=365) against glutamic acid decarboxylase (GADA), islet antigen-2 autoantibodies (IA-2A), or insulin autoantibodies (IAA), in early pregnancy and at delivery were compared to islet autoantibody-negative mothers (n=1457) matched for age and sampling date. Mothers were genotyped for HLA-DQ and analyzed for both EV-RNA and EV-IgM. EV-IgM, but not EV-RNA, was detected during early pregnancy in 12% of islet autoantibody-positive mothers compared to 11% of the controls. In early pregnancy, mothers with HLA-DQ 2/2 or 2/X genotypes showed an increased risk for islet autoantibodies at delivery (OR 1.85; p=0.001). After adjusting for parity, maternal age, year of birth, and season of early pregnancy, early pregnancy EV-IgM combined with DQ2/2 or 2/X increased the risk for islet autoantibodies (OR 3.10; 95% CI 1; p=0.008). EV-IgM in early pregnancy increased the risk for islet autoantibodies at delivery in non-diabetic mothers with HLA-DQ 2/2 or 2/X type 1 diabetes risk genotypes.

Keywords

  • Immunology in the medical area

Other

Published
  • Diabetes and Celiac Unit
  • Paediatric Endocrinology
  • ISSN: 0882-8245
E-mail: ake [dot] lernmark [at] med [dot] lu [dot] se

Principal investigator

Diabetes and Celiac Unit

+46 40 39 19 01

+46 70 616 47 79

60:11:015

Jan Waldenströms gata 35, Malmö

33

Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00